209 related articles for article (PubMed ID: 16029143)
1. Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1.
Shehu-Xhilaga M; Tachedjian G; Crowe SM; Kedzierska K
Curr Med Chem; 2005; 12(15):1705-19. PubMed ID: 16029143
[TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
3. Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors.
Benito JM; López M; Martín JC; Lozano S; Martínez P; González-Lahoz J; Soriano V
AIDS Res Hum Retroviruses; 2002 Dec; 18(18):1379-88. PubMed ID: 12487809
[TBL] [Abstract][Full Text] [Related]
4. HAART-persistent HIV-1 latent reservoirs: their origin, mechanisms of stability and potential strategies for eradication.
Kulkosky J; Bray S
Curr HIV Res; 2006 Apr; 4(2):199-208. PubMed ID: 16611058
[TBL] [Abstract][Full Text] [Related]
5. Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1.
Shafer RW; Vuitton DA
Biomed Pharmacother; 1999 Mar; 53(2):73-86. PubMed ID: 10337461
[TBL] [Abstract][Full Text] [Related]
6. Reservoirs of HIV replication after successful combined antiretroviral treatment.
Belmonte L; Baré P; de Bracco MM; Ruibal-Ares BH
Curr Med Chem; 2003 Feb; 10(4):303-12. PubMed ID: 12570703
[TBL] [Abstract][Full Text] [Related]
7. Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy.
Saksena NK; Potter SJ
AIDS Rev; 2003; 5(1):3-18. PubMed ID: 12875103
[TBL] [Abstract][Full Text] [Related]
8. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.
Hogg RS; Bangsberg DR; Lima VD; Alexander C; Bonner S; Yip B; Wood E; Dong WW; Montaner JS; Harrigan PR
PLoS Med; 2006 Sep; 3(9):e356. PubMed ID: 16984218
[TBL] [Abstract][Full Text] [Related]
9. Obstacles to successful antiretroviral treatment of HIV-1 infection: problems & perspectives.
Potter SJ; Chew CB; Steain M; Dwyer DE; Saksena NK
Indian J Med Res; 2004 Jun; 119(6):217-37. PubMed ID: 15243161
[TBL] [Abstract][Full Text] [Related]
10. [Genotypic resistance to antiretroviral drugs in patients with therapeutic failure to highly active antiretroviral therapy].
Gutiérrez F; Moltó J; Escolano C; Mora A; Pasquau F; Gregori J; Nogueira E
Med Clin (Barc); 2000 Oct; 115(11):401-4. PubMed ID: 11093841
[TBL] [Abstract][Full Text] [Related]
11. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.
Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M
AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 drug resistance and associated factors among adults failing first-line highly active antiretroviral therapy in Ho Chi Minh City, Vietnam.
Pham QD; Huynh TK; Luong TT; Tran T; Vu TX; Truong LX
HIV Clin Trials; 2013; 14(1):34-44. PubMed ID: 23372113
[TBL] [Abstract][Full Text] [Related]
13. "Virostatics" as a potential new class of HIV drugs.
Kelly LM; Lisziewicz J; Lori F
Curr Pharm Des; 2004; 10(32):4103-20. PubMed ID: 15579091
[TBL] [Abstract][Full Text] [Related]
14. The effect of HAART on humoral immune response in primary HIV-1 infected patients.
Pastori C; Barassi C; Lillo F; Longhi R; Capiluppi B; Nozza S; Galli A; Uberti-Foppa C; Lazzarin A; Tambussi G; Lopalco L
J Biol Regul Homeost Agents; 2002; 16(1):9-17. PubMed ID: 12003182
[TBL] [Abstract][Full Text] [Related]
15. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T; McArthur J; Siliciano RF
Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
[TBL] [Abstract][Full Text] [Related]
16. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy.
Kulkosky J; Nunnari G; Otero M; Calarota S; Dornadula G; Zhang H; Malin A; Sullivan J; Xu Y; DeSimone J; Babinchak T; Stern J; Cavert W; Haase A; Pomerantz RJ
J Infect Dis; 2002 Nov; 186(10):1403-11. PubMed ID: 12404155
[TBL] [Abstract][Full Text] [Related]
17. The development of anti-HIV-1 drugs.
Lu XF; Chen ZW
Yao Xue Xue Bao; 2010 Feb; 45(2):165-76. PubMed ID: 21348415
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children.
Delaugerre C; Warszawski J; Chaix ML; Veber F; Macassa E; Buseyne F; Rouzioux C; Blanche S
J Med Virol; 2007 Sep; 79(9):1261-9. PubMed ID: 17607781
[TBL] [Abstract][Full Text] [Related]
19. Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy.
Bart PA; Rizzardi GP; Tambussi G; Chave JP; Chapuis AG; Graziosi C; Corpataux JM; Halkic N; Meuwly JY; Munoz M; Meylan P; Spreen W; McDade H; Yerly S; Perrin L; Lazzarin A; Pantaleo G
AIDS; 2000 Sep; 14(13):1887-97. PubMed ID: 10997391
[TBL] [Abstract][Full Text] [Related]
20. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]